A Phase 3 interventional study of Budesonide/formoterol pMDI 40/2.25ug + spacer and Budesonide/formoterol pMDI 40/2.25 ug in Asthma, sponsored by AstraZeneca. Completed at 11 sites in 3 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2012-04-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.
Among the 359 studies in Asthma by AstraZeneca, this one is the 149th largest by enrollment of the 248 interventional ones that give a count, is one of 18 that started in 2007, is one of 121 in phase 3, and was the 69th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in China
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Czechia and 4 more countries
Ages 4–11
By country, each count listing its studies:
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
359 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 52 · Phase 3 123 · Phase 4 23
First in 1996; this study’s year is marked. 18 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 175 across the 248 interventional studies, 500 across the 110 observational. Of the 330 that completed or were terminated, 129 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
13 of the studies in Asthma by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
| NCT07218172AstraZenecaCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 359 studies in Asthma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare Symbicort pMDI with and without spacer in terms of steroid potency, improvement of lung function and asthma symptoms in children with asthma (6-11 years).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Budesonide/formoterol pMDI 40/2.25ug + spacer
Drug: Budesonide/formoterol pMDI 40/2.25ug + spacer
Budesonide/formoterol pMDI 40/2.25 ug
Drug: Budesonide/formoterol pMDI 40/2.25 ug
Urinary Free Cortisol (UFC)
Ratio between the value at the end of treatment and the value at start of treatment, including only patients with values at both baseline and end of treatment
Time frame: At baseline and 4 weeks
Forced Expiratory Volume in 1 Second (FEV1)
Changes in FEV1 from baseline to the mean value at 2 weeks to 4 weeks with the baseline value as a covariate.
Time frame: At baseline, at 2 weeks and 4 weeks
Morning Peak Expiratory Flow (mPEF)
Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry were estimated using linear interpolation.
Time frame: Daily during run-in and daily during treatment period of 6 weeks
Evening Peak Expiratory Flow (ePEF)
Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation. Missing data between the first and last entry were estimated using linear interpolation.
Time frame: Daily during run-in and daily during treatment period of 6 weeks
Asthma Symptoms at Night
Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
Time frame: Daily during run-in and daily during treatment period of 6 weeks
Asthma Symptoms at Day
Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
Time frame: Daily during run-in and daily during treatment period of 6 weeks
Percentage of Nights With Awakenings Due to Asthma
Change in Percentage of nights with awakenings, average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.
Time frame: Daily during run-in and daily during treatment period of 6 weeks
Use of Rescue Medication at Night
Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.
Time frame: Daily during run-in and daily during treatment period of 6 weeks
Use of Rescue Medication at Day
Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.
Time frame: Daily during run-in and daily during treatment period of 6 weeks
137 subjects enrolled; 30 non randomised: 26 failed inclusion criteria, 2 voluntary discontinuations, 1 incorrect enrolment, 1 adverse event. 107 subjects were randomised
| Milestone | With Spacer | Without Spacer |
|---|---|---|
| Started | 55 | 52 |
| Completed | 55 | 52 |
| Not completed | 0 | 0 |
Ratio between the value at the end of treatment and the value at start of treatment, including only patients with values at both baseline and end of treatment
| Ratio | With Spacer | Without Spacer |
|---|---|---|
| Urinary Free Cortisol (UFC) | 0.86 (0.20 to 2.4) | 1.03 (0.12 to 5.4) |
Changes in FEV1 from baseline to the mean value at 2 weeks to 4 weeks with the baseline value as a covariate.
| Liters | With Spacer | Without Spacer |
|---|---|---|
| Forced Expiratory Volume in 1 Second (FEV1) | 0.17 ± -0.38 | 0.14 ± -0.34 |
Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry were estimated using linear interpolation.
| Liters/min | With Spacer | Without Spacer |
|---|---|---|
| Morning Peak Expiratory Flow (mPEF) | 28.70 ± 24.6 | 19.50 ± 25.1 |
Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation. Missing data between the first and last entry were estimated using linear interpolation.
| Liters/min | With Spacer | Without Spacer |
|---|---|---|
| Evening Peak Expiratory Flow (ePEF) | 27.00 ± 27.7 | 15.30 ± 23.0 |
Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
| Units on a scale | With Spacer | Without Spacer |
|---|---|---|
| Asthma Symptoms at Night | -0.20 ± 0.46 | -0.21 ± 0.39 |
Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
| Units on a scale | With Spacer | Without Spacer |
|---|---|---|
| Asthma Symptoms at Day | -0.25 ± 0.43 | -0.28 ± 0.41 |
Change in Percentage of nights with awakenings, average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.
| Percentage of nights | With Spacer | Without Spacer |
|---|---|---|
| Percentage of Nights With Awakenings Due to Asthma | -13.80 ± 27.2 | -8.20 ± 23.8 |
Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.
| Inhalations | With Spacer | Without Spacer |
|---|---|---|
| Use of Rescue Medication at Night | -0.21 ± 0.50 | -0.14 ± 0.38 |
Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.
| Inhalations | With Spacer | Without Spacer |
|---|---|---|
| Use of Rescue Medication at Day | -0.30 ± 0.56 | -0.19 ± 0.41 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| With Spacer | — | 0/55 (0%) | 0/55 (0%) |
| Without Spacer | — | 0/52 (0%) | 0/52 (0%) |
| Age Continuous(years) | With Spacer | Without Spacer | Total |
|---|---|---|---|
| Mean | 8.6 (6 to 11) | 8.9 (6 to 11) | 8.7 (6 to 11) |
| Sex: Female, Male(Participants) | With Spacer | Without Spacer | Total |
|---|---|---|---|
| Female | 21 | 22 | 43 |
| Male | 34 | 30 | 64 |
The record gives a start of Sep 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.